Clal Biotechnology Industries (XTAE:CBI) Total Liabilities: ₪18.95 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:CBI Clal Biotechnology Industries Ltd XTAE:CBI
18 GF Score
Price ₪0.24
! 3 Warning Signs
View Full Analysis

What is Clal Biotechnology Industries Total Liabilities?

Clal Biotechnology Industries XTAE:CBI -0.42% 18 Total Liabilities is ₪18.95 Mil as of Dec. 2025. GuruFocus rates XTAE:CBI with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Clal Biotechnology Industries's Total Liabilities for the quarter that ended in Dec. 2025 was ₪18.95 Mil.

Clal Biotechnology Industries's quarterly Total Liabilities declined from Dec. 2024 (₪21.52 Mil) to Jun. 2025 (₪19.52 Mil) and declined from Jun. 2025 (₪19.52 Mil) to Dec. 2025 (₪18.95 Mil).

Clal Biotechnology Industries's annual Total Liabilities declined from Dec. 2023 (₪36.98 Mil) to Dec. 2024 (₪21.52 Mil) and declined from Dec. 2024 (₪21.52 Mil) to Dec. 2025 (₪18.95 Mil).

Clal Biotechnology Industries Total Liabilities Historical Data

* Premium members only.

The historical data trend for Clal Biotechnology Industries's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clal Biotechnology Industries Total Liabilities Chart

Clal Biotechnology Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.55 37.79 36.98 21.52 18.95

Clal Biotechnology Industries Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.98 24.38 21.52 19.52 18.95
XTAE:CBI
18GF Score
Clal Biotechnology Industries Ltd XTAE:CBI
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clal Biotechnology Industries Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Clal Biotechnology Industries's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.556+(1.396+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=18.95

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=41.828-22.876
=18.95

Clal Biotechnology Industries's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.556+(1.396+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=18.95

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=41.828-22.876
=18.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₪18.95 Mil mean?
Clal Biotechnology Industries (XTAE:CBI) has a Total Liabilities of ₪18.95 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Clal Biotechnology Industries and its competitors.
Is Clal Biotechnology Industries' Total Liabilities too high?
Clal Biotechnology Industries' current Total Liabilities is ₪18.95 Mil. Overall, Clal Biotechnology Industries has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Clal Biotechnology Industries' Total Liabilities compare to VRTX and REGN?
Clal Biotechnology Industries' Total Liabilities of ₪18.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Clal Biotechnology Industries and its competitors. Clal Biotechnology Industries's current Total Liabilities is ₪18.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clal Biotechnology Industries stock overvalued right now?
Clal Biotechnology Industries (XTAE:CBI) has a current Total Liabilities of ₪18.95 Mil. The current Total Liabilities is ₪18.95 Mil. Clal Biotechnology Industries' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Clal Biotechnology Industries (XTAE:CBI), the current Total Liabilities is ₪18.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clal Biotechnology Industries Business Description

Address Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.
18GF Score

Get the complete analysis for XTAE:CBI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.24
Price